United Kingdom

People: Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

15 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Mesburis, Paul 

Mr. Paul Mesburis is Independent Director of ProMetic Life Sciences Inc. Mr. Mesburis is the Managing Principal of Empyrean Capital, and has more than twenty years of international experience in financial and capital markets. His capital markets experience encompasses senior roles for both buy-side and sell-side firms. On the buy-side, he has managed portfolios for global investment strategies in both debt and equities. On the sell-side, his experience includes senior roles in mergers and acquisitions, investment banking, and institutional equity research at HSBC Securities, Scotiabank Global Banking and Markets and Deutsche Bank Securities. His views on investments have been quoted in the media, including Report on Business of The Globe and Mail and the Financial Post, as well as the subject of features on BNN - Business News Network. In 2012, he was honoured with a Canadian Lipper Fund Award which recognizes funds that have excelled in delivering consistently strong risk-adjusted performance, relative to their peers. He received his Master of Business Administration degree from the Schulich School of Business at York University, his Bachelor of Arts degree from the University of Toronto, and has completed Executive Education at Harvard Business School. Mr. Mesburis holds the Chartered Professional Accountant (Ontario), Certified Public Accountant (Illinois), and a Chartered Financial Analyst designations. He is a member of the Institute of Corporate Directors. Mr. Mesburis serves on the board of directors and is the Chair of the Audit Committees of Avivagen Inc. and EEStor Corp. In addition, he is the Lead Director of Avivagen Inc. and Co-Chair of EEStor Corp.

Basic Compensation

Total Annual Compensation, CAD 77,350
Restricted Stock Award, CAD --
Long-Term Incentive Plans, CAD --
All Other, CAD 84,409
Fiscal Year Total, CAD 161,759

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Simon Best


Bruce Pritchard


John Moran


Patrick Sartore


Gary Bridger


Stefan Clulow

As Of  31 Dec 2017